MONMOUTH JUNCTION, N.J.–Xenomics, Inc. (PINKSHEETS: XNOM), a developer of non-invasive next-generation molecular diagnostics, announced today that it will begin offering a gender prediction test as a service to expectant mothers who are interested in learning the gender of their baby as early as the 7th week of their pregnancy, much earlier than the availability of reliable ultrasound results. The Xenomics test is based on the detection of male-specific Y chromosome sequences in maternal urine using the Company’s proprietary technology for the analysis of Transrenal DNA (Tr-DNA). The service is designed and offered solely for an expectant mother’s information and does not provide any medical diagnoses or guidance. Visitors to the Company’s website www.xenogentest.com can order a test kit containing materials and instructions for the collection of a urine sample and the submission of a sample to the Company for analysis. The Company will report the predicted gender of their baby, as indicated by its test, within 5 to 8 days of sample submission.

Xenomics intends to initially offer its test solely on a direct-mail basis through its website and has contracted with Simbiosys Biowares of Dallas, Texas, a clinical laboratory, for certain analytical laboratory services in support of its testing operations. The Company is also currently working under an agreement with The Genetic Testing Laboratories, Inc. of LasCruces, New Mexico, an experienced provider of genetic testing services, to explore opportunities to widen the distribution of its test to consumers and alternatives for expanding its marketing, laboratory and other commercial capabilities. In addition, Xenomics will continue to seek additional services on a contract basis and complete distribution and partnership arrangements with third parties.

Previously, the Company announced data on its test from a collaborative project with Dr. Warsof of Eastern Virginia Medical School. In this study of 173 pregnant women, the Xenomics test detected male-specific Y chromosome sequences in 95.1% of women pregnant with male fetuses. In the limited number of urine samples collected in the first trimester, the test was 100% sensitive. As discussed in the study, because of the potential for false-positive results, care must be taken by the mother during sample collection to minimize the risk of introducing male DNA from other sources. The study, entitled “Optimization of Transrenal DNA Analysis: Detection of Fetal DNA in Maternal Urine” by Shekhtman et al., was published online in the Early Edition of Clinical Chemistry at http://www.clinchem.org/.

About Xenomics

Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA including miRNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.

Forward-Looking Statements

Statements about the Company’s expectations, the significance of clinical study results, applications of its technology, markets, and other statements that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, dependence on key personnel, obtaining financing and other factors discussed in the Company’s periodic reports filed with the Securities and Exchange Commission.

More information is available on the Company’s website, www.xenomics.com.